MA47313B1 - Formulations sous-cutanées d'anticorps her2 - Google Patents
Formulations sous-cutanées d'anticorps her2Info
- Publication number
- MA47313B1 MA47313B1 MA47313A MA47313A MA47313B1 MA 47313 B1 MA47313 B1 MA 47313B1 MA 47313 A MA47313 A MA 47313A MA 47313 A MA47313 A MA 47313A MA 47313 B1 MA47313 B1 MA 47313B1
- Authority
- MA
- Morocco
- Prior art keywords
- her2 antibody
- formulations
- subcutaneous formulations
- antibody subcutaneous
- subcutaneous
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000007920 subcutaneous administration Methods 0.000 title abstract 4
- 101150029707 ERBB2 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229960002087 pertuzumab Drugs 0.000 abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 229960000575 trastuzumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Abstract
L'invention concerne des formulations d'anticorps her2 à dose fixe pour une administration sous-cutanée, ainsi que leur utilisation dans le traitement du cancer. Les formulations comprennent des formulations sous-cutanées à dose fixe de pertuzumab et des co-formulations sous-cutanées de pertuzumab et de trastuzumab, et leur utilisation dans le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447359P | 2017-01-17 | 2017-01-17 | |
PCT/US2018/013854 WO2018136412A2 (fr) | 2017-01-17 | 2018-01-16 | Formulations sous-cutanées d'anticorps her2 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47313A MA47313A (fr) | 2019-11-27 |
MA47313B1 true MA47313B1 (fr) | 2020-12-31 |
Family
ID=61800658
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47313A MA47313B1 (fr) | 2017-01-17 | 2018-01-16 | Formulations sous-cutanées d'anticorps her2 |
MA056006A MA56006A (fr) | 2017-01-17 | 2018-01-16 | Formulations sous-cutanées d'anticorps her2 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056006A MA56006A (fr) | 2017-01-17 | 2018-01-16 | Formulations sous-cutanées d'anticorps her2 |
Country Status (26)
Country | Link |
---|---|
US (3) | US10849849B2 (fr) |
EP (2) | EP3570884B1 (fr) |
JP (4) | JP6741875B2 (fr) |
KR (5) | KR20240010538A (fr) |
CN (4) | CN110167594B (fr) |
AU (3) | AU2018210312B2 (fr) |
CA (1) | CA3047349C (fr) |
CR (1) | CR20190376A (fr) |
CY (1) | CY1123586T1 (fr) |
DK (1) | DK3570884T3 (fr) |
ES (1) | ES2835376T3 (fr) |
HR (1) | HRP20201866T1 (fr) |
HU (1) | HUE052551T2 (fr) |
IL (2) | IL267896B (fr) |
LT (1) | LT3570884T (fr) |
MA (2) | MA47313B1 (fr) |
MX (2) | MX2019008350A (fr) |
MY (1) | MY189536A (fr) |
PT (1) | PT3570884T (fr) |
RS (1) | RS61236B1 (fr) |
RU (1) | RU2750821C2 (fr) |
SG (2) | SG10202011384XA (fr) |
SI (1) | SI3570884T1 (fr) |
TW (2) | TW202138007A (fr) |
UA (1) | UA123292C2 (fr) |
WO (1) | WO2018136412A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
UA123292C2 (uk) | 2017-01-17 | 2021-03-10 | Дженентек, Інк. | Рідка фармацевтична композиція, яка містить пертузумаб та трастузумаб |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
US11730698B2 (en) | 2018-07-19 | 2023-08-22 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
EP3849615A1 (fr) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions pour le traitement d'une maladie avec des conjugués immunostimulants |
WO2020060179A1 (fr) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | Formulation de stabilisation d'anticorps trastuzumab exempte d'agent tampon |
BR112021015034A2 (pt) | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | Formulação de anticorpo terapêutico |
KR20220035908A (ko) | 2019-06-19 | 2022-03-22 | 실버백 테라퓨틱스, 인크. | 항-메소텔린 항체 및 이의 면역접합체 |
WO2021096278A1 (fr) * | 2019-11-15 | 2021-05-20 | 삼성바이오에피스 주식회사 | Composition en phase liquide pour médicament à base d'anticorps |
WO2021118930A2 (fr) * | 2019-12-09 | 2021-06-17 | Genentech, Inc. | Formulations d'anticorps anti-pd-l1 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN113827717A (zh) * | 2020-06-23 | 2021-12-24 | 三生国健药业(上海)股份有限公司 | 抗her2单克隆抗体冻干制剂及制备方法 |
IL299376A (en) | 2020-06-29 | 2023-02-01 | Genentech Inc | Fixed dose combination of pertuzumab plus transtuzumab |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
CN114652687B (zh) * | 2020-12-23 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种去岩藻糖基化的抗Her2抗体冻干粉针剂的制备方法 |
AU2021411486A1 (en) * | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2023019556A1 (fr) * | 2021-08-20 | 2023-02-23 | 齐鲁制药有限公司 | Préparation d'anticorps anti-her2 à haute concentration et son utilisation |
WO2023178019A1 (fr) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Polythérapies pour le cancer du sein |
KR20230150203A (ko) * | 2022-04-20 | 2023-10-30 | 주식회사 알토스바이오로직스 | 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0171407B1 (fr) | 1984-01-30 | 1993-11-18 | Imperial Cancer Research Technology Limited | Ameliorations relatives aux facteurs de croissance |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
CA1339946C (fr) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Methode d'ultrapurification pour les polypeptides |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (fr) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
DK0474727T3 (da) | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のneu関連タンパク質の検出及び定量 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
WO1997004801A1 (fr) | 1995-07-27 | 1997-02-13 | Genentech, Inc. | Formulation de proteine lyophilisee isotonique et stable |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
EP0852951A1 (fr) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
DE69938923D1 (de) | 1998-03-27 | 2008-07-31 | Genentech Inc | Synergie zwischen apo-2 ligand und antikörper gegen her-2 |
IL139035A0 (en) | 1998-05-06 | 2001-11-25 | Genentech Inc | Protein purification by ion exchange chromatography |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
JP5623681B2 (ja) | 1999-05-14 | 2014-11-12 | ジェネンテック, インコーポレイテッド | 抗−ErbB2抗体による治療 |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
EP1189634B1 (fr) | 1999-06-25 | 2007-02-28 | Genentech, Inc. | Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2 |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
DE60042693D1 (de) | 1999-08-27 | 2009-09-17 | Genentech Inc | Dosierung für die behandlung mit anti erbb2-antikörpern |
US20200048362A1 (en) | 2000-03-16 | 2020-02-13 | Immunogen, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
ES2331646T3 (es) | 2000-05-19 | 2010-01-12 | Genentech, Inc. | Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb. |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
EP1345968A2 (fr) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees |
US6695940B2 (en) | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
EP1300146A1 (fr) | 2001-10-03 | 2003-04-09 | Boehringer Ingelheim International GmbH | Preparation pharmaceutique pour le traitement des tumeurs mammaires animales |
US20040048525A1 (en) | 2002-01-28 | 2004-03-11 | Sagucio Esteban N. | Watercycle for wet rider |
ES2401428T3 (es) | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
RU2338751C2 (ru) | 2002-07-15 | 2008-11-20 | Дженентек, Инк. | СПОСОБЫ ИДЕНТИФИКАЦИИ ОПУХОЛЕЙ, ВОСПРИИМЧИВЫХ К ЛЕЧЕНИЮ АНТИТЕЛАМИ ПРОТИВ ErbB2 |
US6982719B2 (en) | 2002-07-15 | 2006-01-03 | Sun Microsystems, Inc. | Switching sample buffer context in response to sample requests for real-time sample filtering and video generation |
US7129840B2 (en) | 2002-09-03 | 2006-10-31 | Ricoh Company, Ltd. | Document security system |
EP1543038B2 (fr) | 2002-09-11 | 2020-08-05 | Genentech, Inc. | Purification de proteines |
EP1572972A4 (fr) | 2002-11-21 | 2007-11-21 | Genentech Inc | Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2 |
TW555245U (en) | 2003-01-29 | 2003-09-21 | Hon Hai Prec Ind Co Ltd | Cable connector assembly |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
EP2405015B1 (fr) | 2003-03-05 | 2016-01-06 | Halozyme, Inc. | Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant |
US20050025753A1 (en) | 2003-04-30 | 2005-02-03 | Wei Han | Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells |
EP3722309A1 (fr) | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Réduction de protéine a pendant une chromatographie d'affinité sur protéine a |
WO2005099756A2 (fr) | 2004-04-08 | 2005-10-27 | Agus David B | Antagonistes d'erbb pour le traitement de la douleur |
US7195440B2 (en) | 2004-05-27 | 2007-03-27 | Lambert Charles F | Agricultural silo auger system apparatus and method |
MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
ES2521140T3 (es) | 2004-07-22 | 2014-11-12 | Genentech, Inc. | Composición de anticuerpos de HER2 |
US20060067930A1 (en) | 2004-08-19 | 2006-03-30 | Genentech, Inc. | Polypeptide variants with altered effector function |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
KR20070085855A (ko) | 2004-12-07 | 2007-08-27 | 제넨테크, 인크. | Her 억제제를 이용한 치료를 위한 환자 선택 방법 |
CN101141981A (zh) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
DK1850874T3 (da) | 2005-02-23 | 2013-11-11 | Genentech Inc | Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab |
WO2006096861A2 (fr) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi) |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
MY157955A (en) | 2005-07-06 | 2016-08-30 | Hoffmann La Roche | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
EP1971367A4 (fr) | 2005-12-05 | 2010-04-07 | Trinity Biosystems Inc | Procedes et compositions d'apport sans aiguille de partenaires de liaison |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
WO2007145862A2 (fr) | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Prolongation de la survie de patients cancéreux présentant des niveaux élevés d'egf ou de tgf-alpha |
EP2056874B1 (fr) | 2006-08-21 | 2012-09-19 | F. Hoffmann-La Roche AG | Thérapie tumorale avec anticorps anti-vegf |
WO2008031531A1 (fr) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Thérapie antitumorale avec une combinaison d'anticorps anti-her2 |
EP2132573B1 (fr) | 2007-03-02 | 2014-04-23 | Genentech, Inc. | Elément de prévision de la réponse à un inhibiteur de her |
EP1997534A1 (fr) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Thérapie de combinaison de traitement du cancer comportant de la vinflunine et trastuzumab |
CA2687819A1 (fr) | 2007-06-06 | 2008-12-11 | F.Hoffmann-La Roche Ag | Composition d'un premier anticorps monoclonal non marque se liant a un antigene tumoral et d'un second anticorps monoclonal reactif non croise marque par un marqueur a fluorescence nir |
PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2205242B1 (fr) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation |
PL2565206T3 (pl) | 2007-10-30 | 2017-08-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
TW200942552A (en) | 2008-03-06 | 2009-10-16 | Genentech Inc | Combination therapy with c-Met and HER antagonists |
EP2644204B1 (fr) | 2008-03-18 | 2017-04-19 | Genentech, Inc. | Combinaisons de conjugué de médicament-anticorps anti-HER2 et du pertuzumab |
US9235334B2 (en) | 2008-05-09 | 2016-01-12 | Genesis Industries, Llc | Managing landbases and machine operations performed thereon |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
SG176073A1 (en) | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
SG191014A1 (en) | 2010-12-09 | 2013-07-31 | Genentech Inc | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
EP2683413A1 (fr) | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | Sélection in vivo d'anticorps actifs thérapeutiquement |
JP2012228007A (ja) * | 2011-04-15 | 2012-11-15 | Asmo Co Ltd | バスバー装置、ステータ、モータ及びステータの製造方法 |
UA123092C2 (uk) | 2011-10-14 | 2021-02-17 | Дженентек, Інк. | Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
WO2013096812A1 (fr) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Articles manufacturés et procédés destinés à la coadministration d'anticorps |
SG10201706196XA (en) | 2012-06-08 | 2017-08-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-l1阻害剤併用療法を必要とする患者の同定 |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
EP3800204A1 (fr) | 2013-04-16 | 2021-04-07 | F. Hoffmann-La Roche AG | Variants de pertuzumab et leur évaluation |
PT3083686T (pt) | 2013-12-17 | 2019-12-18 | Hoffmann La Roche | Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos |
WO2015164665A1 (fr) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Méthodes de traitement du cancer du sein précoce avec du trastuzumab-mcc-dm1 et du pertuzumab |
WO2016011422A2 (fr) * | 2014-07-17 | 2016-01-21 | Czerniecki Brian J | Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3 |
ES2949173T3 (es) | 2014-09-15 | 2023-09-26 | Hoffmann La Roche | Formulaciones de anticuerpo |
BR112017004953A2 (pt) | 2014-09-17 | 2017-12-05 | Genentech Inc | imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula |
CN104784105A (zh) * | 2015-04-17 | 2015-07-22 | 北京大学 | 一种单克隆抗体药物的凝胶组合物 |
WO2017087280A1 (fr) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Procédés de traitement d'un cancer positif her2 |
EP3267657A1 (fr) | 2016-07-06 | 2018-01-10 | Siemens Aktiengesellschaft | Système de réseau, connecteur dans le cloud et procédé d'identification d'appareils de réseau |
KR20190075114A (ko) | 2016-11-04 | 2019-06-28 | 제넨테크, 인크. | Her2-양성 유방암의 치료 |
CA3046092A1 (fr) | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Traitement du cancer exprimant her2 avance |
UA123292C2 (uk) | 2017-01-17 | 2021-03-10 | Дженентек, Інк. | Рідка фармацевтична композиція, яка містить пертузумаб та трастузумаб |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
AU2018258263A1 (en) | 2017-04-24 | 2019-10-24 | Genentech, Inc. | ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain |
IL299376A (en) | 2020-06-29 | 2023-02-01 | Genentech Inc | Fixed dose combination of pertuzumab plus transtuzumab |
MX2023000622A (es) | 2020-07-14 | 2023-02-22 | Genentech Inc | Ensayos para combinaciones de dosis fija. |
JP2024501445A (ja) | 2020-12-11 | 2024-01-12 | ジェネンテック, インコーポレイテッド | Her2がんの処置のための併用療法 |
-
2018
- 2018-01-16 UA UAA201906865A patent/UA123292C2/uk unknown
- 2018-01-16 EP EP18713735.1A patent/EP3570884B1/fr active Active
- 2018-01-16 CA CA3047349A patent/CA3047349C/fr active Active
- 2018-01-16 KR KR1020247000861A patent/KR20240010538A/ko not_active Application Discontinuation
- 2018-01-16 MY MYPI2019003540A patent/MY189536A/en unknown
- 2018-01-16 RU RU2019125238A patent/RU2750821C2/ru active
- 2018-01-16 MA MA47313A patent/MA47313B1/fr unknown
- 2018-01-16 TW TW110120880A patent/TW202138007A/zh unknown
- 2018-01-16 CN CN201880006320.4A patent/CN110167594B/zh active Active
- 2018-01-16 RS RS20201430A patent/RS61236B1/sr unknown
- 2018-01-16 EP EP20191022.1A patent/EP3868404A1/fr active Pending
- 2018-01-16 LT LTEP18713735.1T patent/LT3570884T/lt unknown
- 2018-01-16 WO PCT/US2018/013854 patent/WO2018136412A2/fr unknown
- 2018-01-16 SG SG10202011384XA patent/SG10202011384XA/en unknown
- 2018-01-16 MA MA056006A patent/MA56006A/fr unknown
- 2018-01-16 JP JP2019538403A patent/JP6741875B2/ja active Active
- 2018-01-16 TW TW107101603A patent/TWI729259B/zh active
- 2018-01-16 KR KR1020217035253A patent/KR20210134432A/ko not_active Application Discontinuation
- 2018-01-16 CN CN202210487308.8A patent/CN115089704A/zh active Pending
- 2018-01-16 SG SG11201905622VA patent/SG11201905622VA/en unknown
- 2018-01-16 DK DK18713735.1T patent/DK3570884T3/da active
- 2018-01-16 US US15/872,648 patent/US10849849B2/en active Active
- 2018-01-16 MX MX2019008350A patent/MX2019008350A/es active IP Right Grant
- 2018-01-16 SI SI201830154T patent/SI3570884T1/sl unknown
- 2018-01-16 KR KR1020207027536A patent/KR20200113292A/ko not_active Application Discontinuation
- 2018-01-16 CR CR20190376A patent/CR20190376A/es unknown
- 2018-01-16 HU HUE18713735A patent/HUE052551T2/hu unknown
- 2018-01-16 CN CN202311183217.6A patent/CN117752782A/zh active Pending
- 2018-01-16 ES ES18713735T patent/ES2835376T3/es active Active
- 2018-01-16 KR KR1020227041082A patent/KR20220162863A/ko not_active Application Discontinuation
- 2018-01-16 KR KR1020197022054A patent/KR20190104554A/ko not_active IP Right Cessation
- 2018-01-16 PT PT187137351T patent/PT3570884T/pt unknown
- 2018-01-16 CN CN202010484395.2A patent/CN111714630B/zh active Active
- 2018-01-16 AU AU2018210312A patent/AU2018210312B2/en active Active
-
2019
- 2019-07-07 IL IL267896A patent/IL267896B/en unknown
- 2019-07-11 MX MX2020008977A patent/MX2020008977A/es unknown
-
2020
- 2020-05-08 AU AU2020203066A patent/AU2020203066A1/en not_active Withdrawn
- 2020-06-12 JP JP2020102377A patent/JP6769687B1/ja active Active
- 2020-08-07 JP JP2020134301A patent/JP2021006526A/ja not_active Withdrawn
- 2020-11-19 US US16/952,670 patent/US20210085597A1/en active Pending
- 2020-11-23 CY CY20201101105T patent/CY1123586T1/el unknown
- 2020-11-24 HR HRP20201866TT patent/HRP20201866T1/hr unknown
-
2021
- 2021-12-13 IL IL288948A patent/IL288948A/en unknown
-
2022
- 2022-08-22 US US17/821,426 patent/US11654105B2/en active Active
-
2023
- 2023-07-04 JP JP2023110283A patent/JP2023145459A/ja active Pending
- 2023-08-01 AU AU2023210566A patent/AU2023210566A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA41013A (fr) | Compositions comprenant des souches bactériennes | |
MA45029B1 (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
MA44659B1 (fr) | Anticorps anti-tim-3 et compositions | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
EA201992350A1 (ru) | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 | |
MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
MA44560A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
MX2017009047A (es) | Regimen de dosificacion para antagonistas de madcam. | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA38369A1 (fr) | Peptides et compositions pour le traitement d'une lesion de l'articulation | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical |